Learn how Pfizer’s clinical research aims to help advance the treatment of prostate cancer.

Pfizer continues to strive for potential treatment options that may offer new hope for men with prostate cancer. As with many potential treatments, our goal is to help prevent the cancer from advancing further and to improve life expectancy.

We are evaluating study medicines in clinical trials that focus mostly on advanced types of prostate cancer, such as castration-sensitive or castration-resistant prostate cancer. (Learn more about these types of prostate cancer at the bottom of the page.) These studies are researching a study medicine taken along with a currently available standard treatment.

If you or a loved one are considering taking part in a prostate cancer clinical trial, find more information below.

Refine your search

Find a prostate cancer clinical trial

Refine your search by applying one of these filters.

      Age (years)

      Show filters

      Join PfizerLink — a clinical research registry

      Get notified about Pfizer clinical trials that may be right for you — now and over time.

      3 trials found

      Contact us

      For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.

      About prostate cancer

      Prostate cancer occurs when the cells within the prostate gland start to multiply out of control. It is the second most common cancer in American men, after skin cancer.

      When prostate cancer has not spread beyond the prostate, treatment may first involve surgery or radiation to remove the cancer. Initial treatment may also involve medication that aims to keep levels of the male sex hormones low. This is because prostate cancer growth is often driven by male sex hormones, including testosterone.

      Metastatic castration sensitive prostate cancer occurs when the cancer spreads to other parts of the body, or if the cancer is first diagnosed when it has already spread. This type of prostate cancer is still responsive to hormone therapy.

      If hormone therapy no longer stops or slows the cancer, the condition is known as metastatic castration resistant prostate cancer.